Timi has been writing about technology for over a decade, focusing on smartphones, computers, and anything that he finds interesting in the tech space. He started writing for XDA, covering all things ...

Get the latest federal technology news delivered to your inbox. The Department of Veterans Affairs is planning to expand the use of an artificial intelligence tool that records veteran-doctor ...

A Clark County (Wash.) Superior Court judge has ruled that patients don’t have a legal right to access ambient AI recordings physicians use to draft clinical notes, siding with The Vancouver (Wash.) ...

The Flowtica Scribe AI Note-Taking Pen combines the functionality of a traditional writing instrument with advanced AI features, offering a practical way to capture and organize information. According ...

Flowtica has introduced the Scribe + Folio bundle, pairing its Scribe smart pen with a new refillable notebook designed to bring handwritten notes into the company’s digital workflow. The Folio uses ...

The white paper raises concerns about how health systems assess ambient AI scribes and suggests the industry needs more rigorous methods for measuring AI documentation quality and patient safety risks ...

Shares of Scribe Therapeutics, a genetic-medicines company co-founded by Nobel laureate Jennifer Doudna, shot up on their first day of trading Friday, continuing a rebound for biotech IPOs this year.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company is one of a handful ...

For many people, managing a disease means chronic therapy. Scribe Therapeutics has a different vision: genetic medicines that offer durable effects for the masses. With its lead program on a path to ...

Scribe Therapeutics (Nasdaq: SCTX) visits the Nasdaq MarketSite in Times Square. Scribe is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to ...

Scribe Therapeutics Inc. (SCTX) has filed to raise drug development investment in an IPO, according to an S-1 registration statement. The firm is a clinical-stage biopharma developing gene editing ...

Scribe Therapeutics on Monday said it plans to sell 7.15 million shares at between $13 and $15 apiece in its initial public offering. At the $14 midpoint of that price range, the Alameda, Calif., ...